Which sells more: paracetamol or bortezomib?
Paracetamol sells far more than bortezomib. Paracetamol (acetaminophen) is a widely used over-the-counter pain and fever medicine in large consumer markets, with sales driven by broad, everyday use. Bortezomib is an oncology medicine used in specific cancers (for example, multiple myeloma) and is dispensed in a much narrower clinical setting.
Why paracetamol typically has much higher sales
Paracetamol’s demand comes from general symptom treatment across many patient groups, including home use for mild pain and fever. Bortezomib is limited to patients who meet specific treatment indications and usually requires specialist prescribing and administration, which constrains its addressable market.
What could change the comparison?
The only scenario where bortezomib could look closer is if you compare a single product’s sales within a narrow geography, a short time window, or a particular billing channel (for example, hospital procurement versus retail OTC). Even then, paracetamol generally remains the higher-volume medicine overall.
Are there official sales figures to verify?
To give an exact answer (for example, by global annual units or revenue) you would need a specific data source that reports sales by medicine name. With only the drug names provided, I can’t verify exact figures or ranking from a particular dataset.
Sources cited: None (no provided sources containing sales rankings or revenue figures).